# Sacituzumab Govitecan in Primary HER2-negative Breast Cancer

Source: https://onco.cc/trials/nct04595565/  
OnCo record `nct04595565` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of capecitabine, carboplatin, cisplatin and sacituzumab govitecan in triple-negative breast cancer, run by GBG Forschungs GmbH, active but no longer recruiting.

## Summary

Sacituzumab Govitecan in Primary HER2-negative Breast Cancer is a phase 3, randomised interventional study registered as NCT04595565 by GBG Forschungs GmbH, with a registry enrolment figure of 1332 participants, started 2020-10-28 and due to reach its primary completion in 2027-03-30. Interventions recorded: Capecitabine; Carboplatin; Cisplatin; Sacituzumab govitecan. Conditions listed: HER2-negative Breast Cancer; Triple Negative Breast Cancer. Sites: Austria, Belgium, France, Germany, Ireland, Spain, Switzerland. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: SASCIA
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT04595565
- Phase: 3
- Setting: Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA
- Sponsor: GBG Forschungs GmbH
- Enrolled: 1332

## Sources

- ClinicalTrials.gov NCT04595565: https://clinicaltrials.gov/study/NCT04595565

## Connected records

- cancers: [Early triple-negative breast cancer](https://onco.cc/cancers/tnbc-early/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/), [Cytotoxic chemotherapy](https://onco.cc/technologies/cytotoxic-chemotherapy/), [Platinum agents](https://onco.cc/technologies/platinum/)
- drugs: [Capecitabine](https://onco.cc/drugs/capecitabine/), [Carboplatin](https://onco.cc/drugs/carboplatin/), [Cisplatin](https://onco.cc/drugs/cisplatin/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct04595565.json